Literature DB >> 18840909

Prevalence of metabolic syndrome in Chinese renal transplant recipients.

C Y Cheung1, H W Chan, Y L Liu, Y H Chan, H S Wong, W L Chak, K S Choi, K F Chau, C S Li.   

Abstract

OBJECTIVE: To investigate the prevalence of metabolic syndrome in Chinese renal transplant recipients, using two different sets of diagnostic criteria.
DESIGN: Cross-sectional study.
SETTING: Regional hospital, Hong Kong. PATIENTS: All Chinese patients who received solitary living-related or cadaveric kidney transplantation from 1 July 1997 to 31 December 2005 in our hospital with follow-up of more than 6 months were recruited. The diagnosis of metabolic syndrome was made according to the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII) criteria and the International Diabetes Federation criteria.
RESULTS: Using the modified (Asian) NCEP-ATPIII criteria, a total of 39 (32%) of 121 patients had metabolic syndrome, which included 20/69 (29%) of the males and 19/52 (37%) of the females. Using the International Diabetes Federation criteria, metabolic syndrome was diagnosed in 26% of the patients, 22% in males and 31% in females. In our patients, the most common component of metabolic syndrome was hypertension and the least common was low high-density-lipoprotein-cholesterol level. Low high-density-lipoprotein-cholesterol levels were significantly more common in female patients.
CONCLUSION: This study shows that there is a high prevalence of metabolic syndrome in our Chinese renal transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18840909

Source DB:  PubMed          Journal:  Hong Kong Med J        ISSN: 1024-2708            Impact factor:   2.227


  1 in total

1.  Metabolic syndrome in chronic kidney disease and renal transplant patients in North India.

Authors:  Debasish Banerjee; Nihil Chitalia; Rickey Raja; Tharindu Bhandara; Dimitrios Poulikakos; Vivekananda Jha
Journal:  Int Urol Nephrol       Date:  2011-06-10       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.